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Abstract
Introduction: Liver fibrosis is often the first stage of liver disease in people living with HIV (PLWHIV) in industrialized
countries. However, little is known about liver fibrosis and its correlates among PLWHIV in sub-Saharan Africa.
Methods: The study was undertaken in three HIV referral clinics in Côte d’Ivoire, Senegal and Togo. Enrolled PLWHIV
underwent a non-invasive assessment of liver fibrosis combining liver stiffness measure (LSM) with transient elastography
and the aspartate aminotransferase-to-platelet ratio index (APRI). Significant liver fibrosis was defined as LSM ≥7.1 kPa.
Patients were screened for alcohol use (alcohol use disorder identification test (AUDIT)-C questionnaire), hepatitis B virus
(HBV) antigen, hepatitis Delta virus (HDV) antibody and anti-hepatitis C (HCV) antibody. A logistic regression model was used
to identify the factors associated with significant liver fibrosis.
Results: A total of 807 PLWHIV were screened at a median age of 43 years (interquartile range (IQR): 36–50). Their median
CD4 count was 393 cells/mm3 (IQR: 234–563) and 682 (84.5%) were on antiretroviral therapy (ART). The prevalence of
significant fibrosis was 5.3% (3.8–6.7). Infections with HBV and HCV were identified in 74 (9.2%) and nine (1.1%) participants.
Main factors associated with liver fibrosis were alcohol use (AUDIT-C >6): (odds ratio (OR) = 4.0, confidence interval (CI): 1.2–
14.0), (Ref. AUDIT-C <4) and HBV infection (OR = 2.9, CI: 1.2–7.2). Of the 74 patients positively screened for HBV, 50.0% were
on a tenofovir-based ART regimen. Overall, 10% of HIV/HBV coinfected patients were detected with a positive HDV antibody
with a higher prevalence in patients with a significant liver fibrosis (43.0%) compared to others (6.3%) (p = 0.01).
Conclusions: Considering the WHO recommendations to screen for HBV infection and treat co-infected patients with
tenofovir-based ART, screening of alcohol use and brief interventions to prevent alcohol abuse should be implemented in
West Africa, especially in HBV/HIV co-infected patients.
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Introduction
Liver diseases now represent one of the leading causes of
mortality in people living with HIV (PLWHIV) in industria-
lized countries [1,2]. Of these liver-related deaths, over 60%
are attributable to hepatitis C virus (HCV) [3]. According to
the 2013 global burden of disease estimates, sub-Saharan
Africa harbours a particularly high level of liver-related
mortality through cirrhosis and hepatocellular carcinoma
irrespective of HIV status [4]. Chronic infection with hepa-
titis B virus (HBV) represents the main etiologic factor of
liver-related mortality on this continent and is endemic
especially in West Africa [5]. However, one-third of cirrhosis
deaths remain of unknown aetiology [4]. Liver fibrosis is
often a preliminary stage preceding liver diseases. In this
context, a better documentation of the burden of liver
fibrosis and associated factors is now needed.
In 2015, the worldwide estimated number of PLWHIV
was 36.7 million and 70% of them were living in sub-
Saharan Africa [6]. With the expanding access to efficient
antiretroviral therapy (ART) in sub-Saharan Africa, PLWHIV
experienced a prolonged life expectancy and are now
entering into a long-term life plan with co-morbidities
including liver diseases [7,8]. A previous report have identi-
fied PLWHIV as vulnerable to liver fibrosis in a context of no
or limited access to ART in Uganda [9]. The association
between HBV infection and liver fibrosis has been pre-
viously reported among PLWHIV in Nigeria [10]. Aside
HBV infection, there are limited information on other risk
factors of liver fibrosis among African PLWHIV. Indeed, the
respective role of HCV infection and alcohol use has been
understudied so far. Alcohol use was identified as nega-
tively influencing adherence to ART in West Africa but its
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impact on the occurrence of liver disease in this particular
context is less known [11].
Our aim was to estimate de prevalence of liver fibrosis
and investigate associated factors among PLWHIV in care in
West Africa.
Methods
Study population
HIV-positive adults (≥18 years) currently in care were
recruited during a three-month period in three infectious
disease units from referral hospitals in Abidjan (Côte
d’Ivoire), Dakar (Senegal) and Lome (Togo). Facing the
high number of patients attending the clinics, we were
unable to guarantee an exhaustive enrolment procedure.
Indeed, between 200 and 500 patients per week were seen
in consultation in each participating sites. A sampling pro-
cedure was performed to select a representative sample of
patients attending the HIV clinics during the study period.
The recruitment was ensured between two or three days
per week according to operator’s availability. On recruit-
ment days, 10–15 patients could be included. Systematic
sampling, a form of one-stage cluster sampling, was applied
on a daily basis. The sampling frame was the list of patients
planned to attend the centre on the day of inclusion.
Considering a sampling interval k = number of participants
to be included/number of people listed to attend, monitors
were asked to select among the first k patients on this list
and then consecutively include the following patients by
applying this predetermined sampling interval. If the
selected person refused, participation was proposed to
the next person on the waiting list. Patients were included
after approving the study. They were then administered a
standardized case report form in order to collect their
sociodemographic characteristics (gender, age, place of liv-
ing) as well as their addictive behaviours including alcohol
and tobacco use.
Alcohol use during the last 12 months was measured
using the short version of the alcohol use disorder identifi-
cation test (AUDIT-C); a three-item questionnaire, each of
them scored from 0 to 4 points, giving a maximum total
score of 12 points. This test has been specifically designed
to identify individuals for whom the use of alcohol places
them at risk of developing alcohol problems or who are
experiencing such problems. A score ≥4 in men and ≥3 in
women was estimated to have 86% sensitivity and 72%
specificity for risky drinking and/or active alcohol abuse or
dependence [12,13]. Although this screening tool was vali-
dated in population from North America, a previous report
from sub-Saharan Africa showed that brief versions of the
AUDIT may be appropriately used for the screening of
excessive alcohol use in PLWHIV [14]. An additional thresh-
old ≥6 was also considered in order to target participant
with heavy declared alcohol use. Although only studied in
men, this conservative cutoff was associated with a signifi-
cantly increased risk of liver disease, upper gastrointestinal
bleeding or pancreatitis [15]. According to their AUDIT-C
score, patients were thus classified as hazardous drinkers
(AUDIT-C ≥4 in men, ≥3 in women) and heavy drinkers
(AUDIT-C ≥6).
Self-report of tobacco use allowed the classification of
the respondents as non-users, past-users or current users.
The duration of tobacco uses as well as the average num-
ber of cigarettes smoked on a typical day was also reported
for current and past tobacco users. Height and weight were
systematically measured and reported on the case report
form in order to compute the body mass index
(BMI) = weight (kg)/(height (m))2. A cutoff of ≥30 was
used to define obesity.
Information related to the characteristics of HIV infection
including CD4 cell count (last known measure and measure
at first entry into HIV care), the use of ART, current and
past history of ART regimen were extracted from patient
medical records.
Once the questionnaire was administered, all included
patients underwent a blood sample collection and a mea-
sure of liver stiffness measure (LSM) through transient
elastography (see later) on the same day.
Laboratory measurements
Viral hepatitis co-infections were assessed using rapid diag-
nostic tests on patient’s blood samples: Determine® (Alere,
Waltham, MA, United States of America (USA)) for HBs
antigen and Oraquick® (Orasure, Bethlehem, PA, USA) for
anti-HCV antibodies as these tests have shown relatively
good diagnostic accuracy [16,17]. Aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT) and platelet
count were measured for all participants in order to com-
pute the APRI score = defined as ((AST*100)/upper limit of
normal)/platelets (109/l).
Those who were positive for the HBV test underwent
viral load quantification by polymerase chain reaction (PCR)
using the ABBOTT M2000RT (Abbot®) kit in Togo and the
COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) v2.0 (Roche®)
kit in Senegal and Cote d’Ivoire. Results were reported in
international units (UI) per millilitre. A threshold of 2000
UI/ml was considered for clinically significant viral load
replication as suggested in the recent European guidelines
for the management of chronic HBV infection [18]. Total
hepatitis Delta virus (HDV) Ab were detected with ETI-AB-
DELTA-2 (DiaSorin S.A., Antony, France). Frozen plasma
samples of patients screened with a positive HCV test
were centralized in the virology unit in Dakar for HCV
viral load quantification by PCR using the COBAS(R)
AmpliPrep/COBAS(R) TaqMan(R) v2.0 (Roche®) kit.
Samples with detectable HCV viral load were tested for
HCV genotype using an in-house assay. All commercial
laboratory tests were performed according to the manufac-
turer’s specifications.
Transient elastography
All participants were assessed for liver fibrosis using a
portable transient elastography device (Fibroscan E401®,
Echosens, Paris) with an M probe. A single device was
made available for a three-month period in each participat-
ing ward. A maximum of two operators were specifically
trained to perform the examination at each site. All
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operators followed the online formal training and certifica-
tion from the manufacturer. Prior to the study inclusions,
they all went through a practical training session with at
least 50 transient elastography performed, supervised by
an experienced hepatologist before being able to include
patients. The median value of 10 successive validated LSM
was used to represent liver stiffness. To be considered
reliable, the examination must include at least 10 measure-
ments with an interquartile range (IQR) ≤30% of the median
value (IQR/Median LSM ≤30%). Transient elastography
measures were considered very reliable if the IQR/Median
LSM was <0.1 and reliable if IQR/Median LSM was between
0.1 and 0.3 [19]. Participants for who these criteria were
not achieved after several attempts were excluded from the
present analysis.
Statistical analysis
Liver fibrosis was assessed using the combination of the
following two non-invasive tests; transient elastography
and APRI score. The low cutoff value of <0.5 points with
the APRI score was applied to define the absence of sig-
nificant liver fibrosis. Using this threshold, the APRI score
has shown a relatively good negative predictive value (80%
(95% confidence interval (CI): 76–84]), based on a 49%
prevalence of ≥F2 stage using the METAVIR score [20].
Transient elastography was then used with a cutoff value
of LSM ≥7.1 kPa to define the presence of a significant liver
fibrosis and ≥14.5 kPa for cirrhosis. These thresholds for
LSM were reported in a recent meta-analysis as the median
optimal cutoff points to define a significant liver fibrosis
that approximates a ≥F2 METAVIR score (and ≥F4 METAVIR
score for cirrhosis) among populations presenting with var-
ious etiological factors for liver fibrosis [21].
Characteristics of participants with and without severe
significant fibrosis were compared using Pearson’s δ2 test
or Fisher’s exact test when appropriate for categorical
variables and Kruskall-Wallis test for continuous variables.
A multivariable logistic regression using the Firth’s pena-
lized likelihood method for rare events was used to assess
factors associated with significant fibrosis [22]. A stepwise
descending procedure was applied to derive the model that
best predicted the presence of severe liver fibrosis. The
goodness of fit of the model was assessed using the
Akaike Information Criterion (AIC), a lower value of the
AIC suggesting a better prediction of the model. All relevant
potential confounders were included in the initial multi-
variate model. Proportions and odds ratio (OR) estimates
were reported with their 95% CI. All statistical analyses
were performed using SAS software 9.2 (SAS Institute Inc.,
NC, USA).
Ethical considerations
All participants were informed about potential risks and
benefits related to their study participation. Participants
gave their signed informed consent before being included.
The present study has been approved by the national ethic
committees of Côte d’Ivoire (“Comité National d’Ethique
pour la Recherche en Côte d’Ivoire”, approval number:
036/MSLS/CNER-dkn), Senegal (“Comité National d’Ethique
pour la Recherche en Santé au Senegal”, approval number:
3226/MJ/DAP/SMS) and Togo (“Comite de Bioéthique pour
la Recherche en Santé du Togo”, approval number: 004/
2013).
Results
Of the 856 participants solicited, 20 (2.4%) refused to
participate. Among those who agreed to be screened for
liver fibrosis, 29 (3.5%) were excluded from the present
analysis for the following reasons: unreliable LSM
(n = 20), indeterminate/unknown HBV, HCV or HIV status
(n = 4) and age<18 years (n = 5).
A total of 807 HIV-positive patients were finally included
in the analysis. Their median age was 43 years (interquartile
range (IQR): 37–50); their median time since first follow-up
for a positive HIV serology was four years (IQR: 2–8) and
682 (84.5%) of these PLWHIV were taking ART for a median
duration of four years (IQR: 2–7) (Table 1).
Based on transient elastography measures; 127 (15.7%)
patients were identified with a LSM≥7.1 kPa. The agree-
ment rate between the APRI score and transient elastogra-
phy was 74.0% (p <10–4), with a Kappa coefficient of 0.13. A
total of 43 patients presented an APRI score ≥0.5 associated
with a LSM ≥7.1 kPa providing an overall prevalence of
significant fibrosis of 5.3% (95% CI: 3.8–6.7). Three patients
(0.4%) presented with an LSM ≥14.5 kPa suggestive of
cirrhosis, all had an APRI score ≥0.5.
Current and hazardous alcohol uses were reported in 271
(33.6%) and 78 (9.4%) of HIV-positive patients, respectively.
Marked differences were observed by country with 12.5%
and 12.1% of hazardous drinkers in Togo and Côte d’Ivoire
versus 1.4% in Senegal (p <0.0001). Men were also more
likely to consume alcohol with 17.3% of hazardous drinkers
versus 6.1% in women (p <0.0001). A current or past history
of tobacco use was reported by 130 (16.1%) of HIV-positive
patients with a median number of 10 cigarettes (IQR: 4–15)
smoked on a typical day and a median duration of smoking of
15 years (IQR: 7–24).
A total of 74 (9.2%) patients were HBV/HIV co-infected
with significant differences according to clinic: 12.3% in
Senegal, 10.1% in Abidjan and 5.2% in Togo (p = 0.02).
The main characteristics of these HBV/HIV co-infected
patients are presented in Table 2. The prevalence of liver
fibrosis in this sub-group was 9.5% (95% CI: 6.7–16.1). Liver
fibrosis was significantly more frequent in HBV-infected
patients declaring a current alcohol use (21.7%) compared
to no alcohol users (3.9%) (p = 0.01). A high ALT value (>40
IU/ml) was reported in 16 (21.6%) of these HBV/HIV co-
infected patients, with more frequent significant liver fibro-
sis (25.0%) compared to patients with ALT<40 UI/ml (5.2%)
(p = 0.03).
Of the 74 HBV/HIV co-infected patients, 12 (16.2%) were
not treated with ART active against HBV, 25 (33.8%) were
on a lamivudine-based regimen and 37 (50.0%) were on
lamivudine associated with tenofovir. The use of tenofovir
in HBV/HIV co-infected patients varied according to loca-
tion: 54.3% in Abidjan, 61.5% in Dakar and 15.4% in Lome
(p = 0.02).
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Table 1. Characteristics of HIV-infected patients according to the presence of a significant liver fibrosis assessed by non-invasive
markers (n = 807)
No significant liver fibrosis
(n=764)
Significant liver fibrosis
(n=43) p
Total
(N=807)
Age (median, [IQR]) 43 [37 – 50] 45 [40 - 51] 0.26 43 [37 – 50]
Gender, n (%) <0.01
Women 548 (71.7) 22 (51.2) 570 (70.6)
Men 216 (28.3) 21 (48.8) 237 (29.4)
Body mass indexa 0.68
<30 697 (91.2) 40 (93.0) 737 (91.3)
≥30 67 (8.8) 3 (7.0) 70 (8.7)
Referral hospital <0.01
Dakar (Senegal) 208 3 (6.7) 211 (26.1)
Lome (Togo) 228 20 (46.5) 248 (30.7)
Abidjan (Côte d’Ivoire) 328 20 (46.5) 348 (43.2)
AUDIT-Cb score, n (%) <0.0001
< 4c 698 (91.4) 33 (76.7) 731 (90.6)
≥ 4 - 5 43 (5.6) 1 (2.3) 44 (5.4)
≥ 6 23 (3.0) 9 (21.0) 32 (4.0)
Tobacco use 0.38
No 643 (84.1) 34 (79.1) 677 (83.9)
Current/past 121 (15.9) 9 (20.9) 130 (16.1)
Antigen HBs, n (%) 0.10
Negative 697 (91.2) 36 (83.7) 733 (90.8)
Positive 67 (8.8) 7 (16.3) 74 (9.2)
Antibody anti-HCV, n (%) 0.02
Negative 757 (99.1) 41 (95.4) 798 (98.9)
Positive 7 (0.9) 2 (4.6) 9 (1.1)
Last known CD4 count (median, [IQR]), cells/mm3 388 [231 – 550] 321 [222 – 499] 0.29 384 [231 – 546]
First known CD4 count (median, [IQR]), cells/mm3 174 [69 – 299] 225 [134 – 344] 0.26 177 [69 – 300]
Antiretroviral use, years 0.04
≤1 170 (22.2) 16 (37.2) 186 (23.0)
>1 - 5 288 (37.7) 16 (37.2) 304 (37.7)
>5 306 (40.1) 11 (25.6) 317 (39.3)
Antiretroviral regimen 0.36
Not treated 115 (15.1) 10 (23.2) 125 (15.5)
AZT/3TC or FTC/NVP 173 (22.6) 12 (27.9) 185 (22.9)
TDF/3TC or FTC/EFV 163 (21.3) 9 (20.9) 172 (21.3)
AZT/3TC or FTC/EFV 119 (15.6) 3 (7.1) 122 (15.1)
PI-based regimen 148 (19.4) 5 (11.6) 153 (19.0)
Others 46 (6.0) 4 (9.3) 50 (6.2)
aBody mass index (BMI) = weight (kg)/height2 (m), a BMI ≥30 is usually retain to define obesity.
bDeclared alcohol use during the last 12 month assessed with the short version of the alcohol use disorders identification test (AUDIT).
c<3 for women.
HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: Hepatitis C virus; IQR: inter quartile range; AZT: zidovudine; 3TC:
lamivudine; FTC: emtricitabine; NVP: nevirapine; TDF: tenofovir; EFV: efavirenz; PI: protease inhibitors.
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A detectable HBV viral load was reported in 26 (35.1%)
HBV/HIV co-infected patients and eight (10.8%) presented a
significant HBV replication level (>2000 IU/ml). Patients
exposed to lamivudine and/or tenofovir-based ART regi-
mens were more likely to present an undetectable HBV
replication (29.0%) compared to others (66.7%) (p = 0.02).
In the 62 HBV/HIV co-infected patients exposed to lamivu-
dine, a significant HBV replication was reported in 3 (12.0%)
patients on lamivudine and 3 (8.0%) patients on lamivudine
associated with tenofovir (p = 0.5). No significant associa-
tion was reported between the presence of a detectable
HBV viral load and the presence of significant liver fibrosis
(p = 0.76). Of the 70 HBV/HIV co-infected patients who
were tested for HDV antibody, seven patients (10%) were
found to be HDV-positive, with marked differences accord-
ing to country; 23% in Togo, 11% in Côte d’Ivoire and none
in Senegal (p = 0.05). A significant liver fibrosis was
reported in 43% of HDV-positive patients versus 6.3% in
HDV-negative patients (p = 0.01).
A total of nine patients were identified with a positive
HCV infection based on the Oraquick® rapid diagnostic test,
providing an estimated HCV prevalence of 1.1% (95% CI:
0.4–1.8). Of these nine HCV/HIV co-infected patients, five
(2.0%) were from Lome, three (1.4%) from Dakar and one
Table 2. Characteristics of HBV/HIV co-infected patients according to the presence of a significant liver fibrosis
assessed by non-invasive markers (n = 74)
No significant liver fibrosis
(n=67)
Significant liver fibrosis
(n=7) pa
Total
(n=74)
Age (median, [IQR]) 41 [35 – 48] 42 [34 – 57] 0.83 41 [35 – 48]
Gender 0.18
Women 49 (73.1) 3 (43.0) 52 (70.3)
Men 18 (26.9) 4 (57.0) 22 (29.7)
Referral hospital 0.04
Dakar (Senegal) 26 (38.8) 0 (0.0) 26 (35.1)
Lome (Togo) 10 (14.9) 3 (43.0) 13 (17.6)
Abidjan (Côte d’Ivoire) 31 (46.3) 4 (57.0) 35 (47.3)
AUDIT-Cb score, n (%) 0.01
< 4c 49 (73.1) 2 (28.6) 51 (70.0)
≥ 4-5 15 (22.4) 3 (42.9) 18 (24.3)
≥ 6 3 (4.5) 2 (28.6) 5 (6.7)
AST (median, [IQR]) 26 [22 – 40] 39 [34 – 78] 0.01 27 [22 – 40]
ALT (median, [IQR]) 22 [17 – 34] 52 [36 – 77] 0.002 24 [18 – 37]
HBV viral load (IU/L) 0.58
<20 (undetectable) 42 (62.7) 6 (85.7) 48 (64.9)
≥20 – 2 000 17 (25.4) 1 (14.3) 18 (24.3)
≥2 000 8 (11.9) 0 (0.0) 8 (10.8)
HDV Antibodyd 0.02
Negative 59 (93.6) 4 (57.0) 63 (90.0)
Positive 4 (6.4) 3 (43.0) 7 (10.0)
Last known CD4 count 380 [236-487] 335 [245-425] 0.62 376 [243 – 482]
median, [IQR], cells/mm3
ART regimen 0.74
Lamivudine-based 23 (34.3) 2 (28.6) 25 (33.8)
Lamivudine+Tenofovir-based 34 (50.7) 3 (42.8) 37 (50.0)
Other, No ART 10 (14.9) 2 (28.6) 12 (16.2)
Antiretroviral use, years 0.92
≤ 1 16 (23.9) 2 (28.6) 18 (24.3)
>1 – 5 27 (40.3) 3 (42.8) 30 (40.5)
> 5 24 (35.8) 2 (28.6) 26 (35.2)
aFisher’s exact test for categorical variables or Kruskall-Wallis test for continuous variables.
bDeclared alcohol use during the last 12 month assessed with the short version of the alcohol use disorders identification
test (AUDIT).
c<3 for women.
dOnly 70 of the 74 HIV/HBV co-infected patients were effectively tested for total HDV antibody.
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(0.3%) form Abidjan. Six had a detectable HCV viral load
with a median value of 6.1 (IQR: 5.5–6.3) log UI/ml. Of the
six patients with a detectable HCV viral load, three of these
viruses were genotype 2, one genotype 1 and two could
not be typed. One patient presented with a triple infection
HCV/HBV and HIV.
In a multivariate analysis, factors associated with a sig-
nificant liver fibrosis were a positive HBs antigen (OR = 2.5;
95% CI: 1.1–6.1), heavy alcohol use defined by an AUDIT
score ≥6 (OR = 4.3; 95% CI: 1.7–10.8] (ref AUDIT score <4)
and participating sites: Lome: (OR = 4.6 (95% CI: 1.4–15.2)),
Abidjan (OR = 3.6 (95% CI: 1.2–11.3)) (reference: Dakar)
(Table 3). Obesity was not associated with significant liver
fibrosis (OR = 0.9 (95% CI: 0.3–2.7)). Table 3 presents
covariates included in the final logistic model with their
unadjusted and adjusted OR and respective 95% CI. A CD4
count measurement <200 cells/mm3, at last follow-up visit
or at first entry into care, were not associated with liver
fibrosis with OR of 0.9 (95% CI: 0.4–2.0) and 0.6 (95% CI:
0.3–1.8), respectively. These covariates were thus not
retained in the final multivariate model.
Discussion
The prevalence of liver fibrosis in our HIV-positive popula-
tion was relatively low compared to previous estimates
from sub-Saharan Africa. In Nigeria, Hawkins et al reported
a prevalence of severe liver fibrosis of 4.7% in HIV mono-
infected patients and 22.6% in HBV/HIV co-infected
patients relying solely on transient elastography and using
Table 3. Factors associated with significant liver fibrosis in HIV-infected patients attending referral HIV clinics in
Abidjan, Dakar and Lome, West Africa (n = 807)
Univariate analysis Multivariable analysis
n/N OR (95% CI) p OR (95% CI) p
Age 0.15 0.11
≤40 years
>40 years
12/313
31/494
1
1.6 (0.8–3.2)
1
1.8 (0.9–3.6)
Gender <0.01 0.07
Women
Men
22/570
21/237
1
2.4 (1.3–4.5)
1
1.8 (0.9–3.5)
Referral hospital 0.02 0.04
Dakar, Senegal
Abidjan, Côte d’Ivoire
Lome, Togo
3/211
20/348
20/248
1
3.7 (1.2–11.7)
5.3 (1.7–16.9)
1
3.6 (1.2–11.3)
4.6 (1.4–15.2)
Alcohol use, <0.0001 <0.01
AUDIT-c scorea
<4b
≥4–5
≥6
25/536
11/237
7/34
1
0.7 (0.1–3.9)
8.4 (3.6–19.5)
1
0.5 (0.1–2.5)
4.3 (1.7–10.8)
Antigen HBsc 0.07 0.04
Negative
Positive
36/733
7/74
1
2.1 (0.9–4.9)
1
2.5 (1.1–6.1)
Anti-HCV antibodyd 0.02 0.11
Negative
Positive
41/798
2/9
1
6.1 (1.3–28.4)
1
4.8 (0.8–27.4)
Antiretroviral use 0.05 0.21
≤1
>1–5
>5
16/186
16/304
11/317
1
0.6 (0.3–1.2)
0.4 (0.2–0.8)
1
0.7 (0.3–1.5)
0.5 (0.2–1.1)
n/N: number of HIV-infected patients with significant fibrosis /total number of HIV-infected patients for a specific category.
aDeclared alcohol use during the last 12 month scored with the short version of the alcohol use disorders identification test
(AUDIT-c).
b<3 for women.
cAssessed with a rapid diagnostic test: Determine® (Alere, Waltham, MA, USA).
dAssessed with a rapid diagnostic test: Oraquick® (Orasure, Bethlehem, PA, USA).
HIV: human immunodeficiency syndrome; HCV: hepatitis C virus; OR: odd ratio; CI: confidence interval.
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a LSM cutoff ≥9.3 kPa [10]. Using the same cutoff, another
study in rural Uganda reported a prevalence of 17% of
severe liver fibrosis in PLWHIV [9]. Nevertheless, these
previous findings were reported in a context of limited or
no access to ART. Therefore, ART through HIV viral suppres-
sion, might have directly impacted on liver fibrosis as sug-
gested by a recent cohort study conducted in northern
America that linked HIV replication with the incidence of
liver fibrosis [23]. Although transient elastography is a tech-
nique rapidly mastered and easy to reproduce, it remains
an operator-dependent procedure. An inadequate use of
the device can lead to the overestimation of LSM. The use
of the APRI score to withdrawal patients with false positive
transient elastography measures partly explained the lower
prevalence of liver fibrosis reported in our study. Recent
WHO guidelines for HBV prevention and treatment pro-
mote the use of simple non-invasive biomarkers such as
the APRI score for the follow-up of HBV-infected patients in
resource-limited settings. However, according to a recent
accuracy study using liver biopsy as the gold standard in
patients with chronic HBV infection, the use of the APRI
score for the assessment of liver fibrosis stage performed
poorly in identifying patients with significant fibrosis, espe-
cially if already on antiviral treatment [24,25]. Therefore,
the combination of non-invasive markers like we did in our
study should continue to be investigated for the staging of
liver fibrosis in specific populations such as HBV/HIV co-
infected populations in sub-Saharan Africa.
The high prevalence of positive HBs Ag reported in this
West African HIV-positive population was consistent with
regional prevalence estimates of HBs Ag carriage from the
general population suggesting that the natural history of
HBV acquisition (essentially during early childhood) might
be modestly influenced by HIV infection. Access to ART was
similar in HBV/HIV co-infected patients compared to HIV
mono-infected patients in these referral clinics. Only half of
the HBV-infected patients were on a tenofovir-based regi-
men, which is now recommended as the preferred first line
ART regimen according to the WHO guidelines [7]. Access
to tenofovir varied greatly across these HIV clinics, with a
particularly low access in Togo. Efforts are needed through-
out West Africa to facilitate access to tenofovir in a context
of a high HBV prevalence.
Marked differences were reported in positive HDV Ab
according to country with high prevalence in Côte d’Ivoire
and Togo compared to Senegal in accordance with the
relatively low prevalence of HDV Ab previously reported
in Dakar in HBV-infected blood donors [26]. However, there
are currently limited or no data on HDV prevalence in many
West African countries [27]. Larger prevalence studies are
needed throughout endemic HBV settings to characterize
the true burden of HDV infection. Liver fibrosis was higher
among HBV-infected patients harbouring HDV antibody
supporting the negative impact of HDV in HIV/HBV co-
infected persons already reported in industrialized coun-
tries [28,29].
A low prevalence of HCV infection was observed in our
study population, quite lower than the available regional
estimates (6.7% (95% CI: 4.8–8.5)) from a recent meta-
analysis conducted among HIV-positive persons in sub-
Saharan Africa [30]. These previous estimates also showed
a quite important heterogeneity between countries in West
Africa with HCV prevalence <3% in Senegal and Cote
d’Ivoire while no HCV prevalence data was available for
Togo. Although limited to a selected population of HIV-
positive patients attending referral hospitals, we provide
here HCV prevalence estimates confirmed with HCV nucleic
acid testing. These data will contribute to provide more
robust prevalence estimates to inform prevention and
treatment programmes against HCV infection.
The prevalence of hazardous alcohol use was high in our
population, three-times higher than in our previous survey
conducted five years ago in the same West African network
of HIV clinics [11]. As HIV-positive patients are now on a
long-term treatment plan, they might be more exposed to
alcohol use and thus deserve more preventive and correc-
tive measures. There is thus a need of longitudinal screen-
ing of alcohol use in HIV-positive people in routine care to
identify potential trends in alcohol misuses that might
impact the effectiveness of ART programmes in sub-
Saharan Africa. Heavy alcohol use was identified as a factor
strongly associated with significant liver fibrosis in our
population. The etiologic role of alcohol in the development
of liver fibrosis, and ultimately liver cirrhosis, is well known.
However, the importance of this factor has been neglected
so far in West Africa. The impact of alcohol seems to be
synergic with HBV infection as HBV/HIV co-infected patients
were five times more likely to present a significant liver
fibrosis when declaring a current alcohol use compared to
those declaring no alcohol use.
The majority of HIV-positive participants were currently
on ART. Although, the duration of ART seemed to be
inversely associated with significant liver fibrosis in unad-
justed analysis, this association did not remain significant in
the final multivariate model. There is currently no clear
evidence of a protective effect of ART over time on the
occurrence of liver fibrosis in HIV mono-infected patients
[31,32]. Results from a recent cohort study conducted in
northern America reported that a high HIV viral load was
predictive of incident liver fibrosis [23]. This finding sug-
gests that through its suppressive effect on HIV replication,
ART has the potential to prevent and/or reduce liver fibro-
sis in HIV-positive patients. Conversely, exposure to ART
drug regimens with a known hepatic toxicity could also
promote liver fibrosis [33,34]. The cross-sectional nature
of our study design prevents any causal relation between
ART use and the occurrence of liver fibrosis. Prospective
cohort studies assessing the impact of ART on liver fibrosis
evolution in HIV mono-infected patients over time will be
ultimately needed. Contrarily to previous studies, no asso-
ciation was reported between a low CD4 count and the
presence of a significant liver fibrosis [23]. In our study, CD4
count measures were not considered as a time-dependent
variable but was only assessed twice; at first entry into care
and at last follow-up visit. This approach might have missed
any association between liver fibrosis and CD4 count as we
did not have information on time spent by patients in an
immune-compromised state.
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Limitations
Caution must be taken in the interpretation of the preva-
lence of liver fibrosis. Indeed, there is a clear lack of valida-
tion studies for the chosen thresholds of the APRI score as
well as transient elastography in our specific population,
especially among PLWHIV without HBV infection. This
absence of consensual definition is highlighted by the diver-
sity of thresholds used in previous reports based on transient
elastography in sub-Saharan Africa [9,10,35]. Although
recommended by the WHO in its recent guideline on HBV
care and treatment, the use of the APRI score have shown
poor diagnostic performances among HBV-infected in sub-
Saharan Africa. Although it performed equivalently to tran-
sient elastography for the diagnosis of a significant fibrosis
(≥F2 METAVIR score) in terms of negative predictive value, it
was consistently inferior in terms of positive predictive value
[25,36,37]. There are various reasons for the APRI score to
be falsely elevated in the context of HIV infection due to
both non-liver diseases related elevation of ALT and throm-
bocytopenia. Excluding patients with a positive APRI score
might have prevented this bias. However, the APRI score may
also give rise to false negative results for significant fibrosis
even at a low threshold, for example, through impaired
immune responses giving rise to limited hepatic inflamma-
tion. Excluding patients with a negative APRI score might
have underestimate de true prevalence of significant liver
fibrosis. A significant difference was reported in prevalence
of liver fibrosis according to participating clinics. This geo-
graphical variation might be related to unmeasured con-
founding factors. Indeed, several factors potentially
influencing the occurrence of a liver fibrosis were not mea-
sured in our study such as exposure to aflatoxins or co-
infection with other agents with potential hepatic tropism
such as mycobacterium tuberculosis. An information bias
might have occurred as transient elastography remains an
operator-dependent procedure. To limit this potential effect,
a maximum of two operators were allowed per site and were
trained in a standardized manner. In addition, the use of the
APRI score to define significant liver fibrosis showed the
same tendency with higher prevalence of liver fibrosis
(APRI score ≥0.5) in Lome and Cote d’Ivoire compared to
Senegal. Self-reported alcohol use is subjected to underre-
porting of the true level of alcohol consumption. To ensure
that participants freely declared their personal alcohol use,
participants were informed that responses provided during
the interview will be anonymously recorded. None of their
responses will have any negative impact on their access to
care. In addition, all clinical monitors that administered the
AUDIT-C were previously trained to characterize the stan-
dard unit of alcohol intake and its various correspondences.
Cutoffs used to define excessive alcohol use with AUDIT-C
relied on validation studies conducted in North American
populations. There is thus a need of further studies to assess
these optimal cutoffs in sub-Saharan Africa. To date, there
are no studies from sub-Saharan Africa demonstrating the
diagnostic accuracy of the Oraquick test for the screening for
HCV infection. Previous reports have point out a risk of
overestimation of HCV prevalence with classical immunoas-
say technics potentially related to cross reaction with
parasitic infections such as schistosomiasis [38,39].
However, the relatively low prevalence of HCV infection
reported in our study confirmed by HCV viral quantification
might limit this bias in the estimation of HCV prevalence.
Finally, our study population might not be fully representa-
tive of all HIV-positive patients in care in West Africa as they
were followed in referral wards with potential differences
compared to patients followed in community-based HIV
clinics.
Conclusions
Heavy alcohol use was not uncommon among HIV-positive
patients and identified as an important determinant of liver
fibrosis in this West African population. HBV infection was
also significantly associated with liver fibrosis and seems to
have a synergic effect with alcohol use on the presence of
liver fibrosis.
Screening of alcohol use and specific interventions to
prevent alcohol abuse should be systematically proposed
to HIV-positive persons in care in West Africa.
Despite the latest WHO recommendation promoting
tenofovir-based first-line ART, access to this drug is still
challenging in many parts of Africa. Thus, the screening of
HBV infection remains a priority to ensure enhanced access
to anti-HBV active drugs in HIV/HBV co-infected persons in
sub-Saharan Africa. In addition, the identification of chronic
Ag HBs carriers among PLWHIV is also crucial for a baseline
assessment of the impact of HBV on the liver and for
screening purpose to prevent hepatocellular carcinoma.
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